TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Perfusion index ratio at 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family Cohesion
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Increase in moderate and vigorous physical activity minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced quantity of alcohol intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced frequency of alcohol intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of binge eating disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WSRS responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events during Treatment (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: HPV vaccine neutralizing antibody detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 50% effect concentration of alfentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 95% effect concentration of alfentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood Pressure Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Cerebral oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neural flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Suicidal thoughts
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion attaining at least a 2 point reduction in pain on Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion attaining 90% and 50% pain relief on Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return of at least 50% baseline pain on Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Pediatric Lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of assessments for the Hill classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathic Pain Questionnaire (NPQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Serious Adverse Events (SAEs) and New-Onset Chronic Illness (NOCI)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer (GMT) post immunization of Anti-pneumolysin (PLY) and anti-choline binding protein A (CbpA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with an adverse birth outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Performance on Fitts' Head Turning Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the CQUPLE intervention to patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of the CQUPLE intervention to providers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the CQUPLE intervention (recruitment)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Determination of Recommended Phase II dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate as Assessed by the Investigator according to RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients requiring mechanical thrombectomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Electrical brain activity in response to visual stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Stress Task-Induced Anxiety as Measured by Visual Analogue Mood Scale (VAMS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Clinician-Rated Liebowitz Social Anxiety Scale (LSAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in percentage ventilated volume of lung (%VV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in alveolar thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent of 20 Weeks Abstinent From Stimulants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in number of days with respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for rebronchoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: EHR documentation of consideration for liver transplantation change
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: EHR documentation of goals of care conversation change
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in sensitivity for diagnosing ALS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence and severity of treatment-related adverse events (TRAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of adverse events of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percentage of participants experiencing adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percentage of participants experiencing dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum plasma concentration of KZR-261
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of new stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Self-reported distress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetic parameters of 5-MeO-DMT and bufotenine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tampa Scale for Kinesiophobia
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee injury and osteoarthritis outcome score-physical function short-form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Turkish Version of the Computer System Usability Questionnaire-Short Version
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of lower extremity movement during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of caregivers who enroll in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of participants who complete their telehealth visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Global score of disordered eating psychopathology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Steroid Free Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new diagnoses of ADRD and MCI
Endpoint domain: Mortality/survival
Primary endpoint: care confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pathologic complete response in the breast and lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Curve (AUC) of Poziotinib and Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Poziotinib and Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Clearance (CL/F) of Poziotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Concentration (Tmax) for Poziotinib and Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Occurrence of RT-PCR-Positive Symptomatic COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Degree of oxaliplatin-induced peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative neurocognitive disorder day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: proportion of patients with a risky stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Primary Patency of Target Lesion (Cephalic Arch)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Primary Patency of Access Circuit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Visual performance (high and low contrast acuity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dolutegravir AUC during standard-dose rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dolutegravir AUC during high-dose rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cerebrospinal fluid protein marker concentration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composition of the microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary ultrasound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Multiple Sclerosis Quality of Life-54 (MSQOL-54)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Borg Dyspnea scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acromiohumeral Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of cytokine assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD14++CD16+ monocytes/macrophages correlates with disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of conversion of sustained post-operative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative volume of FFP transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Radiographic Progression-Free-Survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of portal vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: BCG Uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acromiohumeral interval change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotator Cuff Integrity and Graft Incorporation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of Heavy Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intraoperative and post-operative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Positive resection Margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Lymph node yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in PFC-PPC effective connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PFC-PPC activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: remission of psychiatric symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent area reduction of study ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Musculoskeletal Disorders Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood Samples Extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aneurysm occlusion at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Restless Legs Syndrome severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of irreversibly oxidized albumin HNA-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of albumin binding and detoxification efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicidal behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of all-cause infections
Endpoint domain: Adverse events/effects
Primary endpoint: FEUrea levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immunotherapy efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervention completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Microvascular architecture in the transplant kidney
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Microvascular dynamics in the transplanted kidney
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinically Important Improvement on ONE Functional Outcome Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in retinal pigment epithelium (RPE) thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in photoreceptor thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readiness status for discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of BKV viremia
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in clinical activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in health literacy score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence, severity, and causality of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of blastocyst development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of successful intubations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Feasibility of Information Sheet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptibility of Decision Aid Tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: m-SARA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Skill learning accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Skill learning speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: prevalence of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of traumatic experiences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of difficulties in emotion regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: dropout rate from treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: suicide behaviour while in treatment
Endpoint domain: Adverse events/effects
Primary endpoint: self-harm behaviour while in treatment
Endpoint domain: Adverse events/effects
Primary endpoint: participation in DBT-SUD skills sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Score on Pain Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Tramadol Pills Taken
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulative incidence of grade II-IV aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: 18-f FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of required revisions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with minimal residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Motor-evoked potential (MEP) amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiovascular function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neuromuscular function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Before/After Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to nature-based walking program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Digital Addiction Risk Level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total sitting time/workday
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sitting time/9-h working time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report sedentary behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: physiological stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade ≥3 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinically Significant Changes in Clinical Laboratory Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAg seroclearance/seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite of all-cause death, myocardial infarction, and target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of technical delivery in stimulating target nerves or muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessment of the required stimulation amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pure Tone Audiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distortion Product Otoacoustic Emissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event Questionnaire
Endpoint domain: Adverse events/effects
Primary endpoint: Change rate of MDS-UPDRS III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Perceived clinical benefits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Body fat composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of clinical attachment level (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation from baseline of IL6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Variation from baseline of IL10 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Variation from baseline of INFgamma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: %HbA Rate of Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-operative sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: CDR-SB Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive and Negative Affect Scale (Angry)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feeling-Thermometer measure of warmth towards people with substance use disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rating of willingness to have a drug treatment program in their neighborhood
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from baseline in glycogen on Day 14 as measured by 13C MRS of skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite incidence of major adverse cardiac, cerebrovascular and thromboembolic events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in supine exercise PCWP at peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Promis Physical function CAT lower extremity score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clearance of HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of cervical intraepithelial lesion grade 3 or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes